Efficacy and Safety of AR101 in Peanut Allergy: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
Presented at the AAAAI/WAO Joint Congress, March 2018.
The Efficacy of AR101, a Peanut-Derived Pharmaceutical for Oral Immunotherapy (OIT), is Maintained and Tolerability is Increased with Low-Dose Maintenance Therapy
Presented at the AAAAI Annual Meeting, March 2016.
A Novel Characterized Peanut Allergen Formulation (AR101) for Oral Immunotherapy (OIT) Induces Desensitization in Peanut-Allergic Subjects: A Phase 2 Clinical Safety and Efficacy Study
Presented at the EAACI Annual Congress, June 2015.